Personality predicts time to remission and clinical status in hypochondriasis during a 6-year follow-up

Journal of Nervous and Mental Disease

Volumn 202, Issue 5, 2014, Pages 402-407

  Greeven, Anja ^a,b   Van Balkom, Anton J L M ^c   Spinhoven, Philip ^a,b,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Department of Anxiety Disorders PsyQ ^*  (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

clinical status; Cox's regression analysis; follow up; Hypochondriasis; Life Chart Interview; personality; remission

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; ARTICLE; AVOIDANCE BEHAVIOR; COGNITIVE THERAPY; COOPERATION; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; HYPOCHONDRIASIS; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PERSONALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK FACTOR; TELEPHONE INTERVIEW;

ADULT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOCHONDRIASIS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PERSONALITY; PERSONALITY INVENTORY; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REGRESSION ANALYSIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TEMPERAMENT; TIME FACTORS;

EID: 84899922323     PISSN: 00223018     EISSN: 1539736X     Source Type: Journal    
DOI: 10.1097/NMD.0000000000000133     Document Type: Article

References (47)

1. Anthony JC, Vlahov D, Celentano DD, Menon AS, Margolick JB, Cohn S, Polk BF (1991) Self-report interview data for a study of HIV-1 infection among intravenous-drug-usersVDescription of methods and preliminary evidence on validity. J Drug Issues. 21:739-757.
2. Asmundson GJG, Taylor S, Cox BJ (2001) Health anxiety. Chichester, England: John Wiley & Sons Ltd.
3. Barsky AJ, Ahern DK (2004) Cognitive behavior therapy for hypochondriasis: A randomized controlled trial. JAMA. 291:1464-1470.
4. Barsky AJ, Ahern DK, Fama JM, Bailey ED (1998) A prospective 4- to 5-year study of DSM-III-R hypochondriasis. Arch Gen Psychiatry. 55:737-744.
5. Battaglia M, Przybeck TR, Bellodi L, Cloninger CR (1996) Temperament dimensions explain the comorbidity of psychiatric disorders. Compr Psychiatry. 37: 292-298.
6. Bayon C, Hill K, Svrakic DM, Przybeck TR, Cloninger CR (1996) Dimensional assessment of personality in an out-patient sample: Relations of the systems of Millon and Cloninger. J Psychiatr Res. 30:341-352.
7. Clark DM, Salkovskis PM, Hackmann A, Wells A, Fennell M, Ludgate J, Gelder M (1998) Two psychological treatments for hypochondriasis. A randomised controlled trial. Br J Psychiatry. 173:218-225.
8. Cloninger CR, Svrakic DM (1994) Differentiating normal and deviant personality by the seven-factor personality model. New York: Springer Publishing Co.
9. Cloninger CR, Svrakic DM, Przybeck TR (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry. 50:975-990.
10. Cox BJ, Borger SC, Asmundson GJ, Taylor S (2000) Dimensions of hypochondriasis and the five-factor model of personality. Pers Individ Dif. 29:99-108.
11. Duijsens IJ, Spinhoven P, Verschuur M, Eurelings-Bontekoe LH-M (1999) The development of the Dutch Abbreviated Temperament and Character Inventory (TCI-105) [in Dutch]. Ned Tijdschr Psychol. 54:276-283.
12. Fallon BA, Liebowitz MR, Salman E, Schneier FR, Jusino C, Hollander E, Klein DF (1993) Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol. 13:438-441.
13. Fallon BA, Petova E, Skritskaya N, Sacnhez-Lacay A, Schneier F, Vermes D, Liebowitz MR (2008) A double-masked, placebo-controlled study of fluoxetine for hypochondriasis. J Clin Psychopharmacol. 28:638-645.
14. Fallon BA, Schneier FR, Marshall R, Campeas R, Vermes D, Goetz D, Liebowitz MR (1996) The pharmacotherapy of hypochondriasis. Psychopharmacol Bull. 32:607-611.
15. Ferguson E (2000) Hypochondriacal concerns and the five factor model of personality. J Pers. 68:705-724.
16. Ferguson E (2004) Personality as a predictor of hypochondriacal concerns: Results from two longitudinal studies. J Psychosom Res. 56:307-312.
17. First MB, Spitzer RL, Gibbon M, Williams JB (1996) Structured Clinical Interview for DSM-IV Axis I Disorders. New York: New York State Psychiatric Institute.
18. Greeven A, van Balkom A, van der Leeden R, Merkelbach JW, van den Heuvel OA, Spinhoven P (2009) Cognitive behavioral therapy versus paroxetine in the treatment of hypochondriasis: An 18-month naturalistic follow-up. J Behav Ther Exp Psychiatry. 40:487-496.
19. Greeven A, van Balkom AJLM, Visser S, Merkelbach JW, van Rood YR, van Dyck R, Spinhoven P (2007) Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. Am J Psychiatry. 164:91-99.
20. Hardeveld F, Spijker J, De Graaf R, Hendriks SM, Licht CMM, Nolen WA, Beekman ATF (2013) Recurrence of major depressive disorder across different treatment settings: Results from the NESDA study. J Affect Disord. 147:225-231.
21. Hiller W, Leibbrand R, Rief W, Fichter MM (2002) Predictors of course and outcome in hypochondriasis after cognitive-behavioral treatment. Psychother Psychosom. 71:318-325.
22. Hollifield M (2001) Hypochondriasis and personality disturbance. London: Oxford University Press.
23. Hollifield M, Tuttle L, Paine S, Kellner R (1999) Hypochondriasis and somatization related to personality and attitudes toward self. Psychosomatics. 40: 387-395.
24. Hovens J, Giltay EJ, Wiersma JE, Spinhoven P, Penninx B, Zitman FG (2012) Impact of childhood life events and trauma on the course of depressive and anxiety disorders. Acta Psychiatr Scand. 126:198-207.
25. Jacobson NS, Truax P (1991) Clinical-significanceVA statistical approach to defining meaningful change in psychotherapy-research. J Consult Clin Psychol. 59:12-19.
26. Kellner R (1983) Prognosis of treated hypochondriasis: A clinical study. Acta Psychiatr Scand. 67:69-79.
27. Kirmayer LJ, Robbins JM, Paris J (1994) Somatoform disorders: Personality and the social matrix of somatic distress. J Abnorm Psychol. 103:125-136.
28. Kobak KA, Greist JH, Mantle JM, Jefferson JW, Taylor LH, Dottl SL, Katzelnick DJ (1997) A computer-administered telephone interview to identify mental disorders. JAMA. 278:905-910.
29. Lyketsos CG, Nestadt G, Cwi J, Heithoff K (1994) The Life Chart Interview: A standardized method to describe the course of psychopathology. Int J Methods Psychiatr Res. 4:143-155.
30. Noyes R, Happel RL, Yagla SJ (1999) Correlates of hypochondriasis in a nonclinical population. Psychosomatics. 40:461-469.
31. Noyes R, Kathol RG, Fisher MM, Phillips BM, Suelzer MT, Woodman CL (1994) One-year follow-up of medical outpatients with hypochondriasis. Psychosomatics. 35:533-545.
32. Noyes RJ, Watson DB, Letuchy EM, Longley SL, Black DW, Carney CP, Doebbeling BN (2005) Relationship between hypochondriacal concerns and personality dimensions and traits in a military population. J Nerv Ment Dis. 193:110-118.
33. Noyes RJR, Langbehn DR, Happel RL, Stout LR, Muller BA, Longley SL (2001) Personality dysfunction among somatizing patients. Psychosomatics. 42:320-329.
34. Oosterbaan DB, van Balkom AJLM, van Boeijen CA, de Meij TGJ, van Dyck R (2001) An open study of paroxetine in hypochondriasis. Prog Neuropsychopharmacol Biol Psychiatry. 25:1023-1033.
35. Pennebaker JW, Watson D, Kirmayer LJ, Robbins JM (1991) The psychology of somatic symptoms current concepts of somatization: Research and clinical perspectives (pp 21-36). Washington, DC: American Psychiatric Press.
36. Penninx B, Nolen WA, Lamers F, Zitman FG, Smit JH, Spinhoven P, Beekman ATF (2011) Two-year course of depressive and anxiety disorders: Results from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 133:76-85.
37. Pilowsky I (1967) Dimensions of hypochondriasis. Br J Psychiatry. 113:89-93.
38. Schweitzer PJ, Zafar U, Pavlicova M, Fallon BA (2011) Long-term follow-up of hypochondriasis after selective serotonin reuptake inhibitor treatment. J Clin Psychopharmacol. 31:365-368.
39. Speckens AEM, Spinhoven P, Sloekers PPA, Bolk JH (1996a) A validation study of the Whitely Index, the Illness Attitude Scales, and the Somatosensory Amplification Scale in general medical and general practice patients. J Psychosom Res. 40:95-104.
40. Speckens AEM, Van Hemert AM, Spinhoven P, Bolk JH (1996b) The diagnostic and prognostic significance of the Whitely Index, the Illness Attitudes Scales and the Somatosensory Amplification Scale. Psychol Med. 26:1085-1090.
41. Spinhoven P, Elzinga BM, Hovens J, Roelofs K, van Oppen P, Zitman FG, Penninx B (2011) Positive and negative life events and personality traits in predicting course of depression and anxiety. Acta Psychiatr Scand. 124: 462-473.
42. Starcevic V (1990a) Relationship between hypochondriasis and obsessivecompulsive personality disorder: Close relatives separated by nosological schemes? Am J Psychother. 44:340-347.
43. Starcevic V (1990b) Role of reassurance and psychopathology in hypochondriasis. Psychiatry. 53:13.
44. Svrakic DM, Whitehead C, Przybeck TR, Cloninger CR (1993) Differential diagnosis of personality disorders by the seven-factor model of temperament and character. Arch Gen Psychiatry. 50:991-999.
45. Tyrer P, Kelemen A, Fowler-Dixon R, Ferguson B (1991) A plea for the diagnosis of hypochondriacal personality disorder. J Psychosom Res. 34:637-642.
46. Visser S, Bouman TK (2001) The treatment of hypochondriasis: Exposure plus response prevention vs cognitive therapy. Behav Res Ther. 39:423-442.
47. Warwick HMC, Clark DM, Cobb AM, Salkovskis PM (1996) A controlled trail of cognitive-behavioural treatment of hypochondriasis. Br J Psychiatry. 169: 189-195.